Preimplantation Genetics Diagnosis (PGD) Market By Test Type (Chromosomal Abnormalities, Aneuploidy, X-linked diseases, Single Gene Disorders, HLA Typing, Gender selection, Others): Global Opportunity Analysis and Industry Forecast, 2020-2030

Preimplantation Genetics Diagnosis (PGD) Market

Preimplantation genetic diagnosis (PGD) is called as embryo screening. It is a branch of genetics that involves genetic testing of embryos through in vitro fertilization (IVF).

PGD eliminates risk of selective pregnancy termination for couples who are at substantial risk of transferring serious genetic, chromosomal, or hereditary disorders, including  spinal muscular atrophy and cystic fibrosis.

PGD provides effective solution for healthy embryos free from genetic, hereditary, and chromosomal disorders. It is an evolving technique in modern genetic study.  In addition, increase in prevalence of hereditary, chromosomal, and genetic disorders every year that include triploidy, thalassemia, and Duchenne muscular dystrophy (DMD)requires PGD for the diagnosis of mutational changes. Moreover, increase in usage of PGD techniques in selecting human leukocyte antigen (HLA) profile to match existing sibling with disease and sex balancing in family spurred the growth of PGD market. Furthermore, growth in infertility rate and increase in awareness regarding PGD technique boost the growth of the market.

The global PGD market is segmented on the basis of test type and region. By test type, the market is classified into chromosomal abnormalities, aneuploidy, X-linked diseases, single gene disorders, HLA typing, gender selection, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Major players operating in the global market have adopted key strategies such as product launch to strengthen their market outreach and sustain the stiff competition in the market.

COMPETITION ANALYSIS

The major market participants profiled in this report include Agilent Technologies, Inc., CeGaT GmbH, Illumina Inc., Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Natera Inc., PacGenomics, PerkinElmer, Inc., Quest Diagnostics Inc., and Reproductive Genetic Innovations (RGI)

KEY BENEFITS FOR STAKEHOLDERS

The report provides an extensive analysis of the current and emerging PGD market trends and dynamics. 

In-depth market analysis is conducted by constructing market estimations for the key market segments between 2020 and 2030.

Extensive analysis of the PGD market is conducted by following key product positioning and monitoring of the top competitors within the market framework.

A comprehensive analysis of all regions is provided to determine the prevailing opportunities.

The global PGD market forecast analysis from 2021 to 2030 is included in the report.

The key market players within PGD market are profiled in this report and their strategies are analyzed thoroughly, which help understand the competitive outlook of the PGD industry

Scope of Preimplantation Genetics Diagnosis (PGD) Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Chromosomal Abnormalities

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market analysis by country

4.3 Aneuploidy

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market analysis by country

4.4 X-linked diseases

4.4.1 Key market trends, growth factors and opportunities

4.4.2 Market size and forecast, by region

4.4.3 Market analysis by country

4.5 Single Gene Disorders

4.5.1 Key market trends, growth factors and opportunities

4.5.2 Market size and forecast, by region

4.5.3 Market analysis by country

4.6 HLA Typing

4.6.1 Key market trends, growth factors and opportunities

4.6.2 Market size and forecast, by region

4.6.3 Market analysis by country

4.7 Gender selection

4.7.1 Key market trends, growth factors and opportunities

4.7.2 Market size and forecast, by region

4.7.3 Market analysis by country

4.8 Others

4.8.1 Key market trends, growth factors and opportunities

4.8.2 Market size and forecast, by region

4.8.3 Market analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 Asia-Pacific

5.2.1 Key trends and opportunities

5.2.2 Asia-Pacific Market size and forecast, by Test Type

5.2.3 Asia-Pacific Market size and forecast, by country

5.2.3.1 China

5.2.3.1.1 Market size and forecast, by Test Type

5.2.3.2 Japan

5.2.3.2.1 Market size and forecast, by Test Type

5.2.3.3 India

5.2.3.3.1 Market size and forecast, by Test Type

5.2.3.4 South Korea

5.2.3.4.1 Market size and forecast, by Test Type

5.2.3.5 Rest Of Asia Pacific

5.2.3.5.1 Market size and forecast, by Test Type

5.3 LAMEA

5.3.1 Key trends and opportunities

5.3.2 LAMEA Market size and forecast, by Test Type

5.3.3 LAMEA Market size and forecast, by country

5.3.3.1 Latin America

5.3.3.1.1 Market size and forecast, by Test Type

5.3.3.2 Middle East

5.3.3.2.1 Market size and forecast, by Test Type

5.3.3.3 Africa

5.3.3.3.1 Market size and forecast, by Test Type

5.4 North America

5.4.1 Key trends and opportunities

5.4.2 North America Market size and forecast, by Test Type

5.4.3 North America Market size and forecast, by country

5.4.3.1 U.S.

5.4.3.1.1 Market size and forecast, by Test Type

5.4.3.2 Canada

5.4.3.2.1 Market size and forecast, by Test Type

5.4.3.3 Mexico

5.4.3.3.1 Market size and forecast, by Test Type

5.5 Europe

5.5.1 Key trends and opportunities

5.5.2 Europe Market size and forecast, by Test Type

5.5.3 Europe Market size and forecast, by country

5.5.3.1 Germany

5.5.3.1.1 Market size and forecast, by Test Type

5.5.3.2 France

5.5.3.2.1 Market size and forecast, by Test Type

5.5.3.3 U.K.

5.5.3.3.1 Market size and forecast, by Test Type

5.5.3.4 Italy

5.5.3.4.1 Market size and forecast, by Test Type

5.5.3.5 Rest of Europe

5.5.3.5.1 Market size and forecast, by Test Type

6.1. Introduction

6.2. Top winning strategies

6.3. Product Mapping of Top 10 Player

6.4. Competitive Dashboard

6.5. Competitive Heatmap

6.6. Key developments

7.1 Agilent Technologies, Inc.

7.1.1 Company overview

7.1.2 Company snapshot

7.1.3 Operating business segments

7.1.4 Product portfolio

7.1.5 Business performance

7.1.6 Key strategic moves and developments

7.2 cegat gmbh

7.2.1 Company overview

7.2.2 Company snapshot

7.2.3 Operating business segments

7.2.4 Product portfolio

7.2.5 Business performance

7.2.6 Key strategic moves and developments

7.3 Illumina Inc.

7.3.1 Company overview

7.3.2 Company snapshot

7.3.3 Operating business segments

7.3.4 Product portfolio

7.3.5 Business performance

7.3.6 Key strategic moves and developments

7.4 Invitae Corporation

7.4.1 Company overview

7.4.2 Company snapshot

7.4.3 Operating business segments

7.4.4 Product portfolio

7.4.5 Business performance

7.4.6 Key strategic moves and developments

7.5 Laboratory Corporation of America Holdings

7.5.1 Company overview

7.5.2 Company snapshot

7.5.3 Operating business segments

7.5.4 Product portfolio

7.5.5 Business performance

7.5.6 Key strategic moves and developments

7.6 Natera Inc.

7.6.1 Company overview

7.6.2 Company snapshot

7.6.3 Operating business segments

7.6.4 Product portfolio

7.6.5 Business performance

7.6.6 Key strategic moves and developments

7.7 pacgenomics

7.7.1 Company overview

7.7.2 Company snapshot

7.7.3 Operating business segments

7.7.4 Product portfolio

7.7.5 Business performance

7.7.6 Key strategic moves and developments

7.8 PerkinElmer, Inc.

7.8.1 Company overview

7.8.2 Company snapshot

7.8.3 Operating business segments

7.8.4 Product portfolio

7.8.5 Business performance

7.8.6 Key strategic moves and developments

7.9 Quest Diagnostics Inc.

7.9.1 Company overview

7.9.2 Company snapshot

7.9.3 Operating business segments

7.9.4 Product portfolio

7.9.5 Business performance

7.9.6 Key strategic moves and developments

7.10 Reproductive Genetic Innovations (RGI)

7.10.1 Company overview

7.10.2 Company snapshot

7.10.3 Operating business segments

7.10.4 Product portfolio

7.10.5 Business performance

7.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE, 2020-2030,($THOUSAND)

TABLE 2. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR CHROMOSOMAL ABNORMALITIES, BY REGION , 2020-2030,($THOUSAND)

TABLE 3. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET CHROMOSOMAL ABNORMALITIES BY COUNTRY, 2020-2030,($THOUSAND)

TABLE 4. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR ANEUPLOIDY, BY REGION , 2020-2030,($THOUSAND)

TABLE 5. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET ANEUPLOIDY BY COUNTRY, 2020-2030,($THOUSAND)

TABLE 6. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR X-LINKED DISEASES, BY REGION , 2020-2030,($THOUSAND)

TABLE 7. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET X-LINKED DISEASES BY COUNTRY, 2020-2030,($THOUSAND)

TABLE 8. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR SINGLE GENE DISORDERS, BY REGION , 2020-2030,($THOUSAND)

TABLE 9. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET SINGLE GENE DISORDERS BY COUNTRY, 2020-2030,($THOUSAND)

TABLE 10. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR HLA TYPING, BY REGION , 2020-2030,($THOUSAND)

TABLE 11. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET HLA TYPING BY COUNTRY, 2020-2030,($THOUSAND)

TABLE 12. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR GENDER SELECTION, BY REGION , 2020-2030,($THOUSAND)

TABLE 13. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET GENDER SELECTION BY COUNTRY, 2020-2030,($THOUSAND)

TABLE 14. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($THOUSAND)

TABLE 15. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET OTHERS BY COUNTRY, 2020-2030,($THOUSAND)

TABLE 16. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY REGION, 2020-2030,($THOUSAND)

TABLE 17. ASIA-PACIFIC PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE, 2020-2030,($THOUSAND)

TABLE 18. ASIA-PACIFIC PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY COUNTRY, 2020-2030,($THOUSAND)

TABLE 19. CHINA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)

TABLE 20. JAPAN PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)

TABLE 21. INDIA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)

TABLE 22. SOUTH KOREA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)

TABLE 23. REST OF ASIA PACIFIC PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)

TABLE 24. LAMEA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE, 2020-2030,($THOUSAND)

TABLE 25. LAMEA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY COUNTRY, 2020-2030,($THOUSAND)

TABLE 26. LATIN AMERICA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)

TABLE 27. MIDDLE EAST PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)

TABLE 28. AFRICA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)

TABLE 29. NORTH AMERICA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE, 2020-2030,($THOUSAND)

TABLE 30. NORTH AMERICA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY COUNTRY, 2020-2030,($THOUSAND)

TABLE 31. U.S. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)

TABLE 32. CANADA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)

TABLE 33. MEXICO PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)

TABLE 34. EUROPE PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE, 2020-2030,($THOUSAND)

TABLE 35. EUROPE PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY COUNTRY, 2020-2030,($THOUSAND)

TABLE 36. GERMANY PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)

TABLE 37. FRANCE PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)

TABLE 38. U.K. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)

TABLE 39. ITALY PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)

TABLE 40. REST OF EUROPE PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)

TABLE 41.AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT

TABLE 42.AGILENT TECHNOLOGIES, INC.: OPERATING SEGMENTS

TABLE 43.AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO

TABLE 44.AGILENT TECHNOLOGIES, INC.: NET SALES,

TABLE 45.AGILENT TECHNOLOGIES, INC.: KEY STRATERGIES

TABLE 46.CEGAT GMBH: COMPANY SNAPSHOT

TABLE 47.CEGAT GMBH: OPERATING SEGMENTS

TABLE 48.CEGAT GMBH: PRODUCT PORTFOLIO

TABLE 49.CEGAT GMBH: NET SALES,

TABLE 50.CEGAT GMBH: KEY STRATERGIES

TABLE 51.ILLUMINA INC.: COMPANY SNAPSHOT

TABLE 52.ILLUMINA INC.: OPERATING SEGMENTS

TABLE 53.ILLUMINA INC.: PRODUCT PORTFOLIO

TABLE 54.ILLUMINA INC.: NET SALES,

TABLE 55.ILLUMINA INC.: KEY STRATERGIES

TABLE 56.INVITAE CORPORATION: COMPANY SNAPSHOT

TABLE 57.INVITAE CORPORATION: OPERATING SEGMENTS

TABLE 58.INVITAE CORPORATION: PRODUCT PORTFOLIO

TABLE 59.INVITAE CORPORATION: NET SALES,

TABLE 60.INVITAE CORPORATION: KEY STRATERGIES

TABLE 61.LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT

TABLE 62.LABORATORY CORPORATION OF AMERICA HOLDINGS: OPERATING SEGMENTS

TABLE 63.LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT PORTFOLIO

TABLE 64.LABORATORY CORPORATION OF AMERICA HOLDINGS: NET SALES,

TABLE 65.LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY STRATERGIES

TABLE 66.NATERA INC.: COMPANY SNAPSHOT

TABLE 67.NATERA INC.: OPERATING SEGMENTS

TABLE 68.NATERA INC.: PRODUCT PORTFOLIO

TABLE 69.NATERA INC.: NET SALES,

TABLE 70.NATERA INC.: KEY STRATERGIES

TABLE 71.PACGENOMICS: COMPANY SNAPSHOT

TABLE 72.PACGENOMICS: OPERATING SEGMENTS

TABLE 73.PACGENOMICS: PRODUCT PORTFOLIO

TABLE 74.PACGENOMICS: NET SALES,

TABLE 75.PACGENOMICS: KEY STRATERGIES

TABLE 76.PERKINELMER, INC.: COMPANY SNAPSHOT

TABLE 77.PERKINELMER, INC.: OPERATING SEGMENTS

TABLE 78.PERKINELMER, INC.: PRODUCT PORTFOLIO

TABLE 79.PERKINELMER, INC.: NET SALES,

TABLE 80.PERKINELMER, INC.: KEY STRATERGIES

TABLE 81.QUEST DIAGNOSTICS INC.: COMPANY SNAPSHOT

TABLE 82.QUEST DIAGNOSTICS INC.: OPERATING SEGMENTS

TABLE 83.QUEST DIAGNOSTICS INC.: PRODUCT PORTFOLIO

TABLE 84.QUEST DIAGNOSTICS INC.: NET SALES,

TABLE 85.QUEST DIAGNOSTICS INC.: KEY STRATERGIES

TABLE 86.REPRODUCTIVE GENETIC INNOVATIONS (RGI): COMPANY SNAPSHOT

TABLE 87.REPRODUCTIVE GENETIC INNOVATIONS (RGI): OPERATING SEGMENTS

TABLE 88.REPRODUCTIVE GENETIC INNOVATIONS (RGI): PRODUCT PORTFOLIO

TABLE 89.REPRODUCTIVE GENETIC INNOVATIONS (RGI): NET SALES,

TABLE 90.REPRODUCTIVE GENETIC INNOVATIONS (RGI): KEY STRATERGIES LIST OF FIGURES

FIGURE 1.PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET SEGMENTATION

FIGURE 2.PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030

FIGURE 3.PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 11.PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,BY TEST TYPE,2020(%)

FIGURE 12.COMPARATIVE SHARE ANALYSIS OF CHROMOSOMAL ABNORMALITIES PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ANEUPLOIDY PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF X-LINKED DISEASES PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030(%)

FIGURE 15.COMPARATIVE SHARE ANALYSIS OF SINGLE GENE DISORDERS PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030(%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF HLA TYPING PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030(%)

FIGURE 17.COMPARATIVE SHARE ANALYSIS OF GENDER SELECTION PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030(%)

FIGURE 18.COMPARATIVE SHARE ANALYSIS OF OTHERS PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030(%)

FIGURE 19.PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY REGION,2020

FIGURE 20.CHINA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)

FIGURE 21.JAPAN PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)

FIGURE 22.INDIA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)

FIGURE 23.SOUTH KOREA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)

FIGURE 24.REST OF ASIA PACIFIC PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)

FIGURE 25.LATIN AMERICA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)

FIGURE 26.MIDDLE EAST PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)

FIGURE 27.AFRICA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)

FIGURE 28.U.S. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)

FIGURE 29.CANADA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)

FIGURE 30.MEXICO PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)

FIGURE 31.GERMANY PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)

FIGURE 32.FRANCE PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)

FIGURE 33.U.K. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)

FIGURE 34.ITALY PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)

FIGURE 35.REST OF EUROPE PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)

FIGURE 36. TOP WINNING STRATEGIES, BY YEAR

FIGURE 37. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 38. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 39.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 40.COMPETITIVE DASHBOARD

FIGURE 41.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 42.AGILENT TECHNOLOGIES, INC..: NET SALES ,($THOUSAND)

FIGURE 43.CEGAT GMBH.: NET SALES ,($THOUSAND)

FIGURE 44.ILLUMINA INC..: NET SALES ,($THOUSAND)

FIGURE 45.INVITAE CORPORATION.: NET SALES ,($THOUSAND)

FIGURE 46.LABORATORY CORPORATION OF AMERICA HOLDINGS.: NET SALES ,($THOUSAND)

FIGURE 47.NATERA INC..: NET SALES ,($THOUSAND)

FIGURE 48.PACGENOMICS.: NET SALES ,($THOUSAND)

FIGURE 49.PERKINELMER, INC..: NET SALES ,($THOUSAND)

FIGURE 50.QUEST DIAGNOSTICS INC..: NET SALES ,($THOUSAND)

FIGURE 51.REPRODUCTIVE GENETIC INNOVATIONS (RGI).: NET SALES ,($THOUSAND